MEDIFAST INC: stock overview

MEDNYSEConsumer defensive · Miscellaneous Food Preparations & Kindred Products

Price

$12.97

November 13, 2026Market cap $143M

DCF calculator

What Ploutos Investor adds for MEDIFAST

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

MEDIFAST had revenue of $300M over the last 12 months and a net loss of $41M. Revenue fell by 16.2% a year on average over the last 5 years. It holds more cash than debt, by $172M. It pays a dividend yielding 0.12%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$143M
10.99M shares
P/E
–
median of 4 years: 12.1
Revenue, 12 months
$300M
-16.2% a year over 5 years
Net margin
-13.6%
2025: -4.9%, above 22% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-40.0% a year over 2 years

  • 202510-K
    Revenue$386M
  • 202410-K
    Revenue$602M
  • 202310-K
    Revenue$1.1B

Fiscal years in figures

MED's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $193M
$143M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 0.9
0.8
FCF yield 3-year median: 8.8%
–
Earnings yield 3-year median: 1.1%
–

Profitability

Gross margin 
69.2%
Operating margin 
-11.6%
Net margin 3-year median: 0.3%
-13.6%
ROIC 
-13.9%
ROIC, 5-year average 
44.7%
ROE 
-20.7%

Growth

Revenue, yearly change 
-36.0%
EPS, yearly change 
-994.7%
FCF, yearly change 
-92.7%
Revenue, average a year 
-16.2%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$172M
Total debt 
$21M
Of which operating leases 
$21M
Net cash 
$172M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
4.82

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.4%
0.12%
Buybacks 
–
Total returned 
0.12%
Shares, yearly change 
+0.5%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 20).

Gross margin

71.3%

Above 99% of the 63 companies in its industry, and 88% of all.

Operating margin

-3.7%

Above 29% of the 64 companies in its industry, and 27% of all.

Net margin

-4.9%

Above 22% of the 67 companies in its industry, and 24% of all.

ROE

-9.6%

Above 18% of the 57 companies in its industry, and 19% of all.

ROA

-7.7%

Above 19% of the 66 companies in its industry, and 17% of all.

Revenue growth

-36.0%

Above 2% of the 65 companies in its industry, and 2% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
MEDIFAST INC
CIK
910329
Exchange
NYSE
Industry (SIC)
2090 · Miscellaneous Food Preparations & Kindred Products
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
10.99M

Other companies: Consumer defensive

The largest companies of the same sector, each with its own page.

The Consumer defensive sectorAll companies

The full analysis

What do MEDIFAST's filings show?

These are MEDIFAST's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MED

Didn't find what you were looking for?

Ask us
What is MED's market cap?

MEDIFAST INC's market cap is $143M, at a price of $12.97 on November 13, 2026 and 10.99M shares.

How much revenue does MED have?

MEDIFAST had revenue of $300M over the last 12 months. Over the last 5 years it changed by -16.2% a year on average.

Does MED pay a dividend?

Yes. MEDIFAST paid $0.02 per share over the last 12 months, a yield of 0.12% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From MEDIFAST INC's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.